HMOX1 and early-onset autosomal dominant Alzheimer disease: A number of studies have revealed that HO-1 has therapeutic potential under a variety of pathological conditions, including spinal cord injury, Alzheimer’s disease, Parkinson’s disease, and ischemic brain injury (Clark et al., 2003; Motterlini et al., 2005; Morroni et al., 2018; Zheng et al., 2019).